Golotimod SCV 07; Gamma-D-glutamyl-L-tryptophan,98.04%

产品编号:Bellancom-14743| CAS NO:229305-39-9| 分子式:C16H19N3O5| 分子量:333.34

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-14743
650.00 杭州 北京(现货)
Bellancom-14743
1000.00 杭州 北京(现货)
Bellancom-14743
2500.00 杭州 北京(现货)
Bellancom-14743
3500.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

Golotimod SCV 07; Gamma-D-glutamyl-L-tryptophan

产品介绍 Golotimod (SCV 07) 一种具有抗菌活性的免疫调节肽,可显著提高抗结核研究的功效,刺激胸腺和脾细胞增殖,并改善巨噬细胞功能。Golotimod 抑制 STAT3 信号传导并调节接受放疗或放疗与顺铂联合用药的动物模型中口腔粘膜炎的持续时间和严重程度。Golotimod 具有用于研究复发性生殖器单纯疱疹病毒 2 型 (HSV-2)的潜力。
生物活性

Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2).

体外研究
体内研究

Golotimod (SCV-07) (oral gavage or subcutaneous injection, 100 μg/kg, 5 days) reduces experimental recurrent genital HSV-2 disease by oral administration, more importantly, oral SCV07 after fasting shows a greater reduction in incidence and severity than SCV-07 without fasting in female hartley guinea pigs.
Golotimod (SCV-07) (subcutaneous injection, once or twice a day from days 1 to 20, 100 μg/kg) can reduce the severity and duration of acute and split radiation-induced oral mucositis (OM) and short the duration of ulcerative OM in male LVG golden Syrian Hamsters.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female Hartley guinea pigs (250-300 g) infected HSV-2
Dosage: 100 μg/kg
Administration: Oral gavage or subcutaneous injection; 5 days
Result: Reduced incidence of lesions from 55% (one week before treatment) to only 18% by oral administration, and showed no significant reduction in disease by subcutaneous injection of SCV-07.
Animal Model: Male LVG golden Syrian Hamsters weighing approximately 80 g with radiation-induced mucositis
Dosage: 10, 100 μg/kg or 1 mg/kg
Administration: Subcutaneous injection; once or twice a day from days 1 to 20
Result: Showed a peak mucositis of 3.0 on day 18 in the control group compared to only 2.2 in the test group, and the mucositis score in the SCV-07 treated hamsters was only 6.3% compared to 28.1% in the control group at dose of 100 μg/kg.
Significantly decreased the severity and duration of oral mucositis (OM) at dose of 10 μg/kg, 100 μg/kg or 1 mg/kg.
体内研究

Golotimod (SCV-07) (oral gavage or subcutaneous injection, 100 μg/kg, 5 days) reduces experimental recurrent genital HSV-2 disease by oral administration, more importantly, oral SCV07 after fasting shows a greater reduction in incidence and severity than SCV-07 without fasting in female hartley guinea pigs.
Golotimod (SCV-07) (subcutaneous injection, once or twice a day from days 1 to 20, 100 μg/kg) can reduce the severity and duration of acute and split radiation-induced oral mucositis (OM) and short the duration of ulcerative OM in male LVG golden Syrian Hamsters.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female Hartley guinea pigs (250-300 g) infected HSV-2
Dosage: 100 μg/kg
Administration: Oral gavage or subcutaneous injection; 5 days
Result: Reduced incidence of lesions from 55% (one week before treatment) to only 18% by oral administration, and showed no significant reduction in disease by subcutaneous injection of SCV-07.
Animal Model: Male LVG golden Syrian Hamsters weighing approximately 80 g with radiation-induced mucositis
Dosage: 10, 100 μg/kg or 1 mg/kg
Administration: Subcutaneous injection; once or twice a day from days 1 to 20
Result: Showed a peak mucositis of 3.0 on day 18 in the control group compared to only 2.2 in the test group, and the mucositis score in the SCV-07 treated hamsters was only 6.3% compared to 28.1% in the control group at dose of 100 μg/kg.
Significantly decreased the severity and duration of oral mucositis (OM) at dose of 10 μg/kg, 100 μg/kg or 1 mg/kg.
性状Solid
溶解性数据
In Vitro: 

H2O : 125 mg/mL (374.99 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.9999 mL 14.9997 mL 29.9994 mL
5 mM 0.6000 mL 2.9999 mL 5.9999 mL
10 mM 0.3000 mL 1.5000 mL 2.9999 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服